2.55
2.55 (0%)
As of Feb 14, 2025
23andme Holding Co. [ME]
Source:
Company Overview
23andme Holding Co. business is to help people access, understand, and benefit from the human genome. To achieve this, we pioneered direct-to-consumer genetic testing and built the world’s largest crowdsourced platform for genetic research. Our data engine powers our leading direct-to-consumer precision health platform and our genetics driven Research and Therapeutics businesses.
| Country | United States |
| Headquarters | south san francisco, california |
| Phone Number | ( 650 ) 938-6300 |
| Industry | manufacturing |
| CEO | Anne Wojcicki |
| Website | 23andMe.com |
Financial Year:
Financial Overview (Dollars in Millions)
| Revenue | $60.3 |
| Operating Profit | $-35.9 |
| Net Income | $-53 |
| Net Cash | $-131.6 |
Profit Ratios
| Gross Margin | $39.8 |
| Operating Margin | -59.5 |
| Profit as % of Revenues | -75.1% |
| Profit as % of Assets | -15.8% |
| Profit as % of Stockholder Equity | -84.6% |
Management Effectiveness
| Return on Equity | -84.6% |
| Return on Assets | -19.1% |
| Turnover Ratio | 17.9% |
| EBITA | $-35.9 |
Balance Sheet and Cash Flow Measures
| Total Assets | $277.4 |
| Total Liabilities | $214.7 |
| Operating Cash Flow | $-128.9 |
| Investing Cash Flow | $-3 |
| Financing Cash Flow | $0.3 |
